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OBJECTIVES: To assess in a real life setting, the effectiveness,
direct, indirect costs and quality of life of the combined treatment
with Pegasys® and ribavirin in patients with CHC in France.
METHODS: An observational naturalistic study was designed to
prospectively collect health-economic, quality-of-life and clinical
data on a representative sample of newly treated patients. Data
were collected to assess Sustained Virologic Response (SVR). All
medical resource consumptions, sick leave episodes and Quality
of Life data using a speciﬁc instrument: (HQLQ) were collected.
RESULTS: A total of 2101 patients were included of which 70%
were naïve patients and 17% had cirrhosis. The mean age was
47 years and 62% were male. The genotype distribution
was the following: G1 (53%), G2/3 (37%), G4/5 (10%). A SVR
was achieved in 58% of all patients and 63% in the naïve
subgroup (similar to those of the clinical trials -56%—Fried
NEJM, 2002). The mean total direct costs per patient over a
mean period of 36.9 weeks of treatment was €9977, of which
85.7% (€8548) related to Pegasys®/ribavirin alone, 5% (€495)
for hospital care and 5.1% (€513) for biological and viral testing.
A proportion of 26.2% of patients had at least one sick leave
(mean duration: 49.6 days) with a mean allowance per patient of
€636 (6% of direct costs). The mean HQLQ scores were lower
on all dimensions during the course of treatment as compared to
inclusion and then increased 6 months after its end at higher
levels than at inclusion. This improvement was increased in
patients achieving SVR. CONCLUSIONS: This study conﬁrmed
the results from the clinical trials for effectiveness and suggested
a marked impact on quality of life. In terms of budget impact, the
results suggested that the main cost driver was constituted by
pharmaceuticals.
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OBJECTIVES: The study aims to explore the evidence of phar-
macogenomic testing in clinical trials of anti-HIV drugs. This
study reviews the challenges and barriers to pharmacogenomic
research, highlights opportunities, reveals gaps, and aids in iden-
tifying speciﬁc, achievable goals that will advance the ﬁeld.
METHODS: HIV drugs with a conﬁrmed linkage between the
drug and genomic variations exhibited by individuals were iden-
tiﬁed from database (hiv-pharmacogenomics.org). We searched
a clinical trials registry (clinicaltrials.gov) for the prevalence of
pharmacogenomic parameter as outcome measure in studies of
HIV drugs with conﬁrmed linkage. RESULTS: Clinically signiﬁ-
cant and conﬁrmed pharmacogenomic relationships were identi-
ﬁed for seven HIV drugs. Out of the 980 potential studies, 326
(33.3%) met the inclusion criteria. Of the included studies only
28 (8.6%) assessed pharmacogenomic variation as one of the
evaluable parameter (3 as primary, 9 as secondary and 16 as one
of the determinants in study). Use of pharmacogenomic testing
in the included studies was frequently observed in Indinavir
(22.2%) followed by Efavirenz (15.4%), Saquinavir (15.0%),
Abacavir (13.3%), Atazanavir (10.4%), Nevirapine (9.3%) and
Ritonavir (4.0%). The included studies reported were interven-
tional (24) and observational (4), which included 9 randomised
controlled trials. Approximately 57% of the studies were phase
IV post-marketing clinical trial. Out of 28 studies assessing phar-
macogenomic parameter, 11 (39.3%) were sponsored by the
industry, 11 (39.3%) by government agencies, 4 (14.3%) by
universities and 2 (7.1%) by other sources. CONCLUSIONS:
There are several, well-established pharmacogenomic relation-
ships relevant to HIV and its treatments. However, collection of
outcomes data that would support targeting treatments to
patient groups deﬁned through pharmacogenomics is not widely
carried out, without which there is a possibility of ignorance of
outcomes in groups of patients where the treatment effects may
be most clinically signiﬁcant.
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OBJECTIVES: Assessment of patient ﬂow pathway of Severe
Bacterial Infection Cases in Critical Care (Intensive Care Units
[ICUs] or High-Dependency Units [HDUs]). METHODS: The
analysis is based on inpatient hospital admission data from the
National Health Service (NHS)’s Hospital Episode Statistics
(HES) Database for England in 2004–05 and 2005–06. The
sample group was patients in Critical Care with a Finished Con-
sultant Episode (FCE) (period of care under a single consultant
at a single hospital, completed by year-end) that had a primary or
secondary diagnosis for a speciﬁed Severe Bacterial Infection
(SBI). The data extracted contained a count of FCEs, the patient’s
location prior to admission to Critical Care, length of stay,
outcome and destination post-discharge from Critical Care.
RESULTS: In 2005–06, there were 21,601 FCEs with an SBI in
Critical Care for England, increasing from 18,717 FCEs in
2004–05 (15.4% increase). In 2005–06, 56.4% of FCEs
occurred in an ICU, 24.6% in an HDU and 19.1% in an ICU/
HDU combined ward. The majority of SBI patients in ICU,
63.7% (7,759/12,180) came from a non-critical ward (most
commonly Theatre/Recovery 28.5%), 10.9% (1,323/12,180)
from Accident & Emergency and 9.1% (1,108/12,180) came
from an HDU in the same hospital. For SBI patients in HDU,
55.6% (2,952/5,306) came from a non-critical ward (same hos-
pital) and 26.9% (1427/5306) from an ICU (any hospital). Mor-
tality in ICU was 27.2% (3,317/12,180) and in HDU was 10.5%
(556/5306). The majority of surviving SBI patients in ICU,
56.9% (5,045/8,863) moved to a non-critical care ward and
22.1% (1,963/8,863) moved to an HDU in the same hospital.
From HDU, 69.6% (3,308/4,750) moved to a non-critical care
ward (same hospital) and 17.8% (845/4,750) moved to an ICU
(any hospital). CONCLUSIONS: The majority of SBI patients
are admitted to ICUs and HDUs from a non-critical ward in the
same hospital, most commonly Theatre/Recovery.
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